PROTEIN KINASES--MOLECULAR ROLES IN PRODUCING BEHAVIOR
Project Number2R01NS029255-10A1
Former Number5R01NS029255-08
Contact PI/Project LeaderSCHWARTZ, JAMES
Awardee OrganizationCOLUMBIA UNIVERSITY HEALTH SCIENCES
Description
Abstract Text
DESCRIPTION: (from applicant's abstract)
The importance of studying synaptic function at the molecular level is most
obvious for understanding mental and neurological diseases where
psychopharmacological therapeutics, modern molecular genetics and
biochemically-oriented neurophysiology indicate an underlying synaptic malady.
Long-term presynaptic facilitation (LTF) of sensory-to-motor neuron synapses,
which is a form of plasticity underlying behavioral sensitization in the marine
mollusk Aplysia and an elementary form of learning, can be produced by the
action of the cAMP-dependent protein kinase (PKA).
Ubiquitin-proteasome-mediated degradation of PKA regulatory R-subunits occurs
in sensory neurons when treated to produce long-term facilitation; this
molecular change endures only if new protein is made. No change in catalytic
(C) subunits occurs. A decreased R/C ratio produces a kinase that is more
sensitive to subsaturating cAMP and sets the baseline extent of protein
phosphorylation within the neuron at a higher level for at least 24h. The fine
control of cAMP-dependent phosphorylation is mediated by regulated proteolysis
through the ubiquitin-proteasome pathway, which degrades R subunits
selectively. This pathway is up-regulated by the induction of the immediate
early gene Ap -ubiquitin C terminal hydrolase, which enhances proteolysis by
the proteasome. Our first aim is to identify the coupling and ligating enzymes
(E2 and E3) that specifically ubiquitinate R subunits and to determine whether
they are induced during LTF. Why does PKA remain persistently active long after
LTF has been induced? Evidence suggests the regulation of protein synthesis
locally at synapses. We will test the idea that the persistent kinase is
required to produce proteins needed for augumented translation as well as
cytoskeletal proteins for the growth of new synapses.
National Institute of Neurological Disorders and Stroke
CFDA Code
854
DUNS Number
621889815
UEI
QHF5ZZ114M72
Project Start Date
07-January-1992
Project End Date
31-March-2005
Budget Start Date
01-April-2001
Budget End Date
31-March-2002
Project Funding Information for 2001
Total Funding
$359,387
Direct Costs
$225,000
Indirect Costs
$134,387
Year
Funding IC
FY Total Cost by IC
2001
National Institute of Neurological Disorders and Stroke
$359,387
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 2R01NS029255-10A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2R01NS029255-10A1
Patents
No Patents information available for 2R01NS029255-10A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2R01NS029255-10A1
Clinical Studies
No Clinical Studies information available for 2R01NS029255-10A1
News and More
Related News Releases
No news release information available for 2R01NS029255-10A1
History
No Historical information available for 2R01NS029255-10A1
Similar Projects
No Similar Projects information available for 2R01NS029255-10A1